Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Multimodal analgesia better than opioids at dulling pain after penile implants

07 Mar 2020

Multimodal analgesia (MMA) regimens effectively decrease postoperative pain in patients receiving inflatable penile prosthesis (IPP) implants, a recent study has found.

The study included 203 patients undergoing IPP implantation, of whom 103 (mean age, 62.9±8.8 years) were given an MMA protocol consisting of preoperative and postoperative doses of acetaminophen, gabapentin, and meloxicam or celecoxib, with intraoperative administrations of dorsal and pudendal nerve blocks. The remaining 100 patients (mean age, 64.3±10.1 years) were set as opioid-only controls.

The MMA regimen appeared to be superior. Median visual analogue scale (VAS) scores were significantly lower relative to the opioid group in the postanaesthesia care unit (PACU; 0.0 vs 2.0; p=0.01) and at postoperative day 0 (3.0 vs 4.0; p=0.001) and day 1 (3.0 vs 4.3; p=0.04).

Similarly, fewer narcotics were needed in the MMA vs the opioid group while in the PACU (0.0 vs 4.0 total morphine equivalents; p=0.001) and at postoperative day 0 (7.5 vs 12.5 total morphine equivalents; p<0.001) and day 1 (7.5 vs 13.5 total morphine equivalents; p=0.01).

These advantages extended until the time of discharge, at which point patients treated with the MMA protocol were prescribed significantly fewer narcotics (p<0.001) and were less likely to need refills (p=0.001) than their opioid comparators.

Both treatments were comparably tolerated, with no pain medication-related side effects reported in either arm. This included manifestations such as visual changes, haematomas and acute kidney injuries. The rates of postoperative urinary retention (8.7 percent vs 12.5 percent; p=0.49) and pruritis (0.9 percent vs 3.1 percent; p=0.35) also did not differ between groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.